Loading...
XHKG3347
Market cap6.02bUSD
Dec 23, Last price  
32.20HKD
1D
-0.16%
1Q
16.25%
IPO
-71.58%
Name

Hangzhou Tigermed Consulting Co Ltd

Chart & Performance

D1W1MN
XHKG:3347 chart
P/E
21.68
P/S
5.95
EPS
1.39
Div Yield, %
1.26%
Shrs. gr., 5y
2.91%
Rev. gr., 5y
26.27%
Revenues
7.38b
+4.21%
62,792,911122,844,075193,263,834254,315,147336,518,889624,561,658956,997,6821,174,538,2031,687,033,4552,300,659,7062,803,309,2873,192,278,5045,213,538,0547,085,471,4687,384,039,460
Net income
2.02b
+0.91%
7,801,02231,709,27247,791,76167,748,51294,056,536125,496,309156,277,965140,651,982301,013,932472,183,931841,634,8231,749,774,7812,874,163,0202,006,552,0352,024,849,989
CFO
1.15b
-15.25%
21,948,30026,585,75338,691,55014,982,51977,099,58643,660,896185,732,093191,910,992314,970,861522,242,718527,557,935998,675,0961,423,796,2501,357,500,8921,150,437,942
Dividend
Jun 07, 20240.62365 HKD/sh

Profile

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
URL
https://www.tigermedgrp.com/
IPO date
Aug 17, 2012
Employees
9,455
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,384,039
4.21%
7,085,471
35.91%
5,213,538
63.32%
Cost of revenue
5,103,788
4,917,578
3,528,136
Unusual Expense (Income)
NOPBT
2,280,251
2,167,894
1,685,402
NOPBT Margin
30.88%
30.60%
32.33%
Operating Taxes
338,606
313,652
292,864
Tax Rate
14.85%
14.47%
17.38%
NOPAT
1,941,645
1,854,242
1,392,538
Net income
2,024,850
0.91%
2,006,552
-30.19%
2,874,163
64.26%
Dividends
(589,867)
Dividend yield
1.93%
Proceeds from repurchase of equity
(29,850)
90,579
BB yield
0.10%
-0.11%
Debt
Debt current
1,969,694
2,067,697
782,618
Long-term debt
1,280,441
1,222,592
813,678
Deferred revenue
14,786
1
Other long-term liabilities
231,112
73,117
114,881
Net debt
(17,393,095)
(16,362,999)
(16,446,734)
Cash flow
Cash from operating activities
1,150,438
1,357,501
1,423,796
CAPEX
Cash from investing activities
(1,534,225)
Cash from financing activities
(7,806)
809,254
FCF
1,464,621
737,471
766,321
Balance
Cash
7,462,130
7,883,086
8,573,536
Long term investments
13,181,099
11,770,203
9,469,494
Excess cash
20,274,027
19,299,015
17,782,353
Stockholders' equity
13,074,000
11,306,312
9,124,731
Invested Capital
14,437,699
14,066,198
12,503,983
ROIC
13.62%
13.96%
11.21%
ROCE
8.29%
8.47%
7.72%
EV
Common stock shares outstanding
864,949
864,893
870,958
Price
35.35
-60.81%
90.20
-8.89%
99.00
-46.05%
Market cap
30,575,932
-60.81%
78,013,357
-9.52%
86,224,891
-41.19%
EV
16,609,624
64,748,366
72,415,721
EBITDA
2,585,937
2,432,639
1,874,325
EV/EBITDA
6.42
26.62
38.64
Interest
119,897
83,179
24,910
Interest/NOPBT
5.26%
3.84%
1.48%